Format

Send to

Choose Destination
See comment in PubMed Commons below
J Biomol Screen. 2014 Dec;19(10):1372-82. doi: 10.1177/1087057114546551. Epub 2014 Aug 12.

Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays.

Author information

1
Centre for Drug Research and Development, Vancouver, BC, Canada.
2
Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
3
Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada.
4
Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
5
Institute of Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh, UK.
6
Centre for Drug Research and Development, Vancouver, BC, Canada tpfeifer@cdrd.ca.

Abstract

Mutations of DNA repair pathways contribute to tumorigenesis and provide a therapeutic target for synthetic lethal interactions in tumor cells. Given that tyrosyl-DNA phosphodiesterase 1 (Tdp1) repairs stalled topoisomerase-I DNA complexes, we hypothesized that inhibition of Tdp1 has synthetic lethal effects in some cancers. To test this, we screened tumor arrays for Tdp1 expression and observed that Tdp1 is expressed in many tumors, including more than 90% of human breast tumors. Subsequent chemical screening identified putative Tdp1 inhibitors. Treatment of control human mammary epithelial cells and the breast cancer cell line MCF-7 with compound CD00509 preferentially sensitized MCF-7 cells to camptothecin and decreased cell proliferation 25% more than camptothecin treatment alone. This suggests that CD00509 specifically targeted Tdp1 in vitro, and CD00509 increased the sensitivity of wild-type murine embryonic fibroblasts (MEFs) to camptothecin to a degree comparable to that of Tdp1(-/-) MEFs. In addition, consistent with poly ADP-ribose polymerase-1 (PARP-1) collaborating with Tdp1 in DNA repair, combined Tdp1 and PARP-1 inhibition was more detrimental to MCF-7 cells than either treatment alone, whereas the combination was not additively harmful to control mammary cells. We conclude that targeting Tdp1 in anticancer therapy preferentially enhances the sensitivity of some breast cancer cells to camptothecin and may be an effective adjuvant for breast cancer therapy.

KEYWORDS:

cancer and cancer drugs; cell-based assays; compound repositories; high content screening

PMID:
25117203
DOI:
10.1177/1087057114546551
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center